| scholarly article | Q13442814 |
| P50 | author | Stephen Benz | Q30503463 |
| Lance A. Liotta | Q74243861 | ||
| Laura Esserman | Q91960202 | ||
| P2093 | author name string | Michael J Campbell | |
| Emanuel F Petricoin | |||
| Christopher C Benz | |||
| Mary Winters | |||
| Anjali S Kumar | |||
| Frederick Baehner | |||
| Corina Marx | |||
| Yamei Zhou | |||
| Mark Shoemaker | |||
| Margaret Lobo | |||
| Kelly Adduci | |||
| Elizabeth Borman | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 8707-8714 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Breast cancer growth prevention by statins | |
| P478 | volume | 66 |
| Q89185720 | A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model |
| Q33901385 | A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk |
| Q37589128 | A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. |
| Q47130348 | A quality by design approach for the development of lyophilized liposomes with simvastatin. |
| Q89424441 | Aberrant expression of ETS1 and ETS2 proteins in cancer |
| Q36918192 | Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer |
| Q33638286 | Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells |
| Q98163418 | Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer |
| Q43162316 | Antiangiogenic mechanisms of simvastatin in retinal endothelial cells |
| Q65001909 | Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. |
| Q39431398 | Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production |
| Q46792293 | Augmented simvastatin cytotoxicity using optimized lipid nanocapsules: a potential for breast cancer treatment. |
| Q39831618 | Autocrine amplification loop in statin-induced apoptosis of human melanoma cells. |
| Q37323642 | BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases |
| Q38147841 | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates |
| Q47394764 | Biomarker identification for statin sensitivity of cancer cell lines |
| Q92503481 | CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs |
| Q59795879 | Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy |
| Q36153371 | Chemoprevention of hormone receptor-negative breast cancer: new approaches needed |
| Q39720693 | Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death |
| Q39647685 | Combined Inhibitory Effects of Celecoxib and Fluvastatin on the Growth of Human Hepatocellular Carcinoma Xenografts in Nude Mice |
| Q28240913 | Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1 |
| Q36809477 | Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases |
| Q47141363 | Differences of statin activity in 2D and 3D pancreatic cancer cell cultures |
| Q37184792 | Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women |
| Q37015751 | Effect of Lipophilic and Hydrophilic Statins on Breast Cancer Risk in Thai Women: A Cross-sectional Study |
| Q36473929 | Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis |
| Q42920928 | Effects of Pravastatin on Murine Chronic Graft-Versus-Host Disease |
| Q33889477 | Effects of lovastatin on breast cancer cells: a proteo-metabonomic study |
| Q55049353 | Evaluation of the Cytotoxic and Autophagic Effects of Atorvastatin on MCF-7 Breast Cancer Cells |
| Q38572098 | Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems. |
| Q47937818 | Exploring association between statin use and breast cancer risk: an updated meta-analysis. |
| Q33715760 | Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy |
| Q39656423 | Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells |
| Q34277789 | Fluvastatin mediated breast cancer cell death: a proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells |
| Q33864834 | Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer |
| Q54331848 | Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. |
| Q92816025 | HDL and LDL: Potential New Players in Breast Cancer Development |
| Q47655012 | HMG-CoA reductase inhibition delays DNA repair and promotes senescence after tumor irradiation |
| Q37644912 | High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer |
| Q42266154 | Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design |
| Q39643965 | IL-2 Costimulation Enables Statin-Mediated Activation of Human NK Cells, Preferentially through a Mechanism Involving CD56+ Dendritic Cells |
| Q91936936 | Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay |
| Q39043383 | Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells |
| Q58546969 | Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study |
| Q35850911 | Impact of cholesterol on disease progression |
| Q36427010 | In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin |
| Q61443217 | Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells |
| Q63366138 | Inflammatory breast cancer biology: the tumour microenvironment is key |
| Q89902210 | Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review |
| Q35964485 | Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation |
| Q57040662 | Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer |
| Q35856126 | Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells |
| Q88796720 | Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin |
| Q58122649 | Interactions Between Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients |
| Q37001668 | Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer |
| Q28388335 | Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases |
| Q46746321 | Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley |
| Q34185642 | Lipophilic statin use and risk of breast cancer subtypes |
| Q55393652 | Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. |
| Q33512239 | Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein |
| Q33542856 | Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance |
| Q39656742 | Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (hep-g2) growth. |
| Q37402139 | Lovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects model |
| Q91846054 | Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade |
| Q35556776 | Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells |
| Q37783621 | Modern Approach to Metabolic Rehabilitation of Cancer Patients: Biguanides (Phenformin and Metformin) and Beyond |
| Q26797207 | Molecular cancer prevention: Current status and future directions |
| Q37247753 | Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio- and neuroprotection |
| Q24302433 | Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway |
| Q52893748 | Nanostructured lipid carriers loaded with simvastatin: effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity. |
| Q46414473 | No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer |
| Q28066348 | Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer |
| Q36309338 | Novel properties of statins: suppression of the systemic and bone marrow responses induced by exposure to ambient particulate matter (PM(10)) air pollution |
| Q58555566 | Nucleolar stress: is there a reverse version? |
| Q36684403 | Phosphorylation of eIF2α attenuates statin-induced apoptosis by inhibiting the stabilization and translocation of p53 to the mitochondria |
| Q26861053 | Plant sterols as anticancer nutrients: evidence for their role in breast cancer |
| Q26783220 | Pleiotropic effects of statins |
| Q36426544 | Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors |
| Q36906404 | Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. |
| Q38673155 | Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer |
| Q36447926 | Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity |
| Q33796968 | Prevention of ER-negative breast cancer |
| Q37038650 | Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer |
| Q37467715 | Prospective analysis of association between statin use and breast cancer risk in the women's health initiative |
| Q89639335 | Serum Lipidomic Profiling in Breast Cancer to Identify Screening, Diagnostic, and Prognostic Biomarkers |
| Q39434294 | Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression |
| Q35601464 | Simvastatin modulates mesenchymal stromal cell proliferation and gene expression |
| Q37325151 | Simvastatin reduces melanoma progression in a murine model |
| Q37064638 | Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model |
| Q36771848 | Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway |
| Q89634316 | Statin Drugs Plus Th1 Cytokines Potentiate Apoptosis and Ras Delocalization in Human Breast Cancer Lines and Combine with Dendritic Cell-Based Immunotherapy to Suppress Tumor Growth in a Mouse Model of HER-2pos Disease |
| Q47755766 | Statin Use and Breast Cancer Prognosis in Black and White Women |
| Q38741468 | Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma. |
| Q35268601 | Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study |
| Q90074464 | Statin therapy: does sex matter? |
| Q28082068 | Statin use and breast cancer survival and risk: a systematic review and meta-analysis |
| Q36095264 | Statin use and breast cancer survival: a nationwide cohort study in Scotland. |
| Q34021312 | Statin use and cancer risk: a comprehensive review |
| Q34998527 | Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study |
| Q46896215 | Statin use and risk of breast cancer |
| Q57790350 | Statin use and risk of contralateral breast cancer: a nationwide cohort study |
| Q39295852 | Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis |
| Q92740270 | Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study |
| Q35583876 | Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial |
| Q38981350 | Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms |
| Q59126976 | Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters |
| Q34760888 | Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion |
| Q37348597 | Statins Increase Mitochondrial and Peroxisomal Fatty Acid Oxidation in the Liver and Prevent Non-Alcoholic Steatohepatitis in Mice |
| Q35910859 | Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease |
| Q39967982 | Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins |
| Q37239999 | Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency |
| Q34206487 | Statins and breast cancer prognosis: evidence and opportunities. |
| Q58589102 | Statins attenuate outgrowth of breast cancer metastases |
| Q57105348 | Statins: a role in breast cancer therapy? |
| Q39795839 | Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment |
| Q38976416 | Suppressive effects of simvastatin on the human acute promyelocytic leukemia NB4 cell line through the regulation of the nuclear factor-κB signaling pathway |
| Q35648936 | Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment |
| Q40093390 | Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells |
| Q90102543 | Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells |
| Q37190825 | Targeted therapy for breast cancer prevention |
| Q39455228 | Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial |
| Q92667609 | Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer |
| Q38267049 | Targeting the NFκB signaling pathways for breast cancer prevention and therapy. |
| Q37981833 | Targeting tumor cell metabolism with statins. |
| Q28587192 | Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression |
| Q37246561 | The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. |
| Q38791223 | The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer |
| Q37137519 | The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women |
| Q60628576 | The Heterogeneity of Lipid Metabolism in Cancer |
| Q45332064 | The association between statins and cancer incidence in a veterans population |
| Q49346285 | The dichotomous role of H2S in cancer cell biology? Déjà vu all over again |
| Q39359330 | The differential effects of statins on the metastatic behaviour of prostate cancer. |
| Q47731628 | The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study |
| Q38499265 | The effect of statins on cancer cells--review |
| Q60045641 | The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer |
| Q44803322 | The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis |
| Q47944717 | The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer |
| Q36432163 | The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer |
| Q34742771 | Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. |
| Q28077243 | Triple-negative breast cancer: is there a treatment on the horizon? |
| Q35029556 | Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen |
| Q35673791 | Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients |
| Q33548538 | Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer |
| Q28476014 | Utilization of genomic signatures to identify phenotype-specific drugs |
Search more.